Skip to main content
. 2016 Oct 13;9:109. doi: 10.1186/s13045-016-0341-7

Fig. 5.

Fig. 5

a Progression-free survival (PFS) for NKTCL patients with a serum soluble PD-L1 of <3.4 and ≥3.4 ng/ml. b Overall survival (OS) for NKTCL patients with a serum soluble PD-L1 of <3.4 and ≥3.4 ng/ml. c PFS for NKTCL patients with a histological PD-L1 expression of <38 and ≥38 %. c OS for NKTCL patients with a histological PD-L1 expression of <38 and ≥38 %